NM

Naga Maheshwar Reddy Nimmakayala

Active Director Director DIN 11091371
DIN 11091371 First appointment May 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Naga Maheshwar Reddy Nimmakayala

Data last updated:

Naga Maheshwar Reddy Nimmakayala is a Director at Ross Biotech Private Limited (since 2025). The company operates in Pharma.

DIN 11091371
Primary Designation Director
Industry Pharma
First Appointment 06 May 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ross Biotech Private Limited U46599KA2025PTC202367
Director06 May 20252025Active

Board colleagues of Naga Maheshwar Reddy Nimmakayala

Directorship timeline

Open interactive timeline →
Ross Biotech Private Limited
Premium access

Shareholding and investment profile for Naga Maheshwar Reddy Nimmakayala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Naga Maheshwar Reddy Nimmakayala

Naga Maheshwar Reddy Nimmakayala currently holds 1 directorship: Ross Biotech Private Limited (Director, since 06 May 2025).

Naga Maheshwar Reddy Nimmakayala was first appointed on 06 May 2025 as Director at Ross Biotech Private Limited.

The current boards of Naga Maheshwar Reddy Nimmakayala's companies include Pavan Kumar Reddy Nelaturu (Ross Biotech Private Limited), Subasha Hugar Prashanth (Ross Biotech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available